Regulation	O
of	O
thrombospondin	O
-	O
1	O
by	O
natural	O
and	O
synthetic	O
progestins	O
in	O
human	O
breast	B-Cell
cancer	I-Cell
cells	I-Cell
.	O

Our	O
recent	O
studies	O
show	O
that	O
progestins	O
induce	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
breast	B-Cell
cancer	I-Cell
cells	I-Cell
that	O
express	O
mutant	O
p53	O
protein	O
.	O

Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	O
also	O
induce	O
thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
mRNA	O
and	O
protein	O
in	O
T47	B-Cell
-	I-Cell
D	I-Cell
and	O
BT	B-Cell
-	I-Cell
474	I-Cell
breast	I-Cell
cancer	I-Cell
cells	I-Cell
.	O

Antiprogestin	O
RU	O
-	O
486	O
inhibits	O
the	O
induction	O
of	O
VEGF	O
and	O
TSP	O
-	O
1	O
by	O
progestins	O
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	O
is	O
mediated	O
by	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
.	O

Actinomycin	O
-	O
D	O
,	O
but	O
not	O
puromycin	O
,	O
also	O
blocks	O
progestin	O
-	O
dependent	O
induction	O
of	O
TSP	O
-	O
1	O
.	O

A	O
putative	O
progestin	O
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	O
TSP	O
-	O
1	O
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	O
-	O
PR	O
complex	O
might	O
directly	O
regulate	O
transcription	O
of	O
the	O
TSP	O
-	O
1	O
gene	O
in	O
human	O
cells	B-Cell
.	O

Conditioned	O
medium	O
from	O
progestin	O
-	O
treated	O
breast	B-Cell
cancer	I-Cell
cells	I-Cell
stimulates	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	O
to	O
TSP	O
-	O
1	O
,	O
indicating	O
that	O
TSP	O
-	O
1	O
secreted	O
by	O
breast	B-Cell
cancer	I-Cell
cells	I-Cell
could	O
be	O
pro	O
-	O
angiogenic	O
.	O

Since	O
tumor	B-Cell
cell	I-Cell
-	O
derived	O
TSP	O
-	O
1	O
has	O
the	O
potential	O
to	O
promote	O
angiogenesis	O
in	O
the	O
tumor	B-Cancer
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	B-Cancer
cancer	I-Cancer
therapy	O
.	O

